Trial · NCT00038142
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
NCT00038142, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2020-01-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients. Trials, record NCT00038142. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00038142
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
- NCT number
- NCT00038142
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 46 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Ewing's Sarcoma
- Interventions
- Vincristine, Doxorubicin, Cyclophosphamide, Dexrazoxane, ImmTher
- First posted
- 2002-05-30
- Last updated
- 2020-01-29
- Results first posted
- 2020-01-29
- Limitations and caveats
- Study terminated early leading to small numbers of subjects analyzed; therefore, unable to accrue required number of participants to determine statistical significance.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-year Disease-free Survival (DFS): Effect of Treatment With Combination Drugs in VACdxr Given in High Doses With or Without ImmTher to Help Participants With Ewing's Sarcoma Live Longer | 2 years | DFS defined as survival of participants to two years post study entry without relapse. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 2-year Disease-free Survival (DFS): Effect of Treatment With Combination Drugs in VACdxr Given in High Doses With or Without ImmTher to Help Participants With Ewing's Sarcoma Live Longer | 2 years | Data was not collected due to early termination of the protocol |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm A: VACdxr With ImmTher | 32 | |
| Overall Study | STARTED | Arm B: VACdxr | 14 | |
| Overall Study | COMPLETED | Arm A: VACdxr With ImmTher | 10 | |
| Overall Study | COMPLETED | Arm B: VACdxr | 7 | |
| Overall Study | NOT COMPLETED | Arm A: VACdxr With ImmTher | 22 | |
| Overall Study | NOT COMPLETED | Arm B: VACdxr | 7 |
Source ClinicalTrials.gov
Adverse events176
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdomen Pain | Gastrointestinal disorders | Arm A: VACdxr With ImmTher | 1 | 31 | 1 |
| other | Abdomen Pain | Gastrointestinal disorders | Arm B: VACdxr | 0 | 14 | 0 |
| other | Abdominal Cramping | General disorders | Arm A: VACdxr With ImmTher | 0 | 31 | 0 |
| other | Abdominal Cramping | General disorders | Arm B: VACdxr | 1 | 14 | 1 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Arm A: VACdxr With ImmTher | 9 | 31 | 9 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Arm B: VACdxr | 6 | 14 | 6 |
| other | Alanine Aminotransferase/ Serum Glutamic Pyruvic Transamnase | Investigations | Arm A: VACdxr With ImmTher | 1 | 31 | 1 |
| other | Alanine Aminotransferase/ Serum Glutamic Pyruvic Transamnase | Investigations | Arm B: VACdxr | 0 | 14 | 0 |
| other | Amylase Increase | Investigations | Arm A: VACdxr With ImmTher | 1 | 31 | 1 |
| other | Amylase Increase | Investigations | Arm B: VACdxr | 0 | 14 | 0 |
1 to 10 of 176Source ClinicalTrials.gov
See all 176 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm A: VACdxr With ImmTher | ||
| Total, all-cause mortality | Arm B: VACdxr | ||
| Total, other adverse events | Arm A: VACdxr With ImmTher | 31 | 31 |
| Total, other adverse events | Arm B: VACdxr | 14 | 14 |
| Total, serious adverse events | Arm A: VACdxr With ImmTher | 1 | 31 |
| Total, serious adverse events | Arm B: VACdxr | 0 | 14 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Arm A: VACdxr With ImmTher vs Arm B: VACdxr: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00038142
GET https://conductscience.org/api/trials/v1/NCT00038142/events?page=2